Australia's Amplia Therapeutics slips on discounted capital raise
** Amplia Therapeutics ATX.AX slips as much as 14% to A$0.245, lowest since July 4 ** Stock marks biggest intraday pct drop since June 30 ** Drug developer announces capital raise of A$27.5 mln ($18 mln) at issue price of A$0.23, representing 19.3% discount to last close ** Says funds will support ACCENT and AMPLICITY trials, support ovarian cancer trials of co's lead drug, narmafotinib (AMP945 ** Stock last down 10.5%, trims YTD gains to ~192% ($1 = A$1.5253) (Reporting by Anjali Singh in Bengaluru) ((anjali.singh2@thomsonreuters.com;))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement